-+ 0.00%
-+ 0.00%
-+ 0.00%

RTW Biotech's Portfolio Company Alesta Therapeutics Signs Contract for Up to $490 Million Takeover

MT Newswires·08/19/2026 03:21:28
Listen to the news
03:21 AM EDT, 08/19/2026 (MT Newswires) -- RTW Biotech Opportunities' (RTW.L) portfolio company, Alesta Therapeutics, will be acquired by US-based biotechnology company BioMarin Pharmaceutical (BM8.F) in a definitive deal worth up to $490 million, according to a Wednesday filing. BioMarin will pay $275 million cash upfront and up to an additional $215 million on the achievement of certain milestones for Alesta's lead asset ALE1, which is in development for hypophosphatasia. Before deal completion, which is expected in the third quarter of 2026, the clinical-stage biotechnology company will transfer all non-ALE1 assets to a newly-formed entity, in which RTW Bio and other existing Alesta shareholders will retain their pro rata stake. The value of RTW's holding in Alesta was $3.8 million, representing 0.4% of the London-listed life sciences-focused investor's net asset value, as of July 31.